Gregg Gilbert
Stock Analyst at Truist Securities
(2.27)
# 2,736
Out of 5,053 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $13.34 | +27.44% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $42.30 | -12.53% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $46.69 | +79.91% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $924.37 | -43.20% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.56 | +98.17% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $10.92 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $86.28 | +7.79% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $24.23 | +98.10% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.34 | +1,840.30% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.28 | +11,618.75% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $14.44 | +440.17% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $120.24 | -35.13% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $23.97 | -24.91% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $131.16 | +33.42% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $219.16 | -69.89% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $13.34
Upside: +27.44%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $42.30
Upside: -12.53%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $46.69
Upside: +79.91%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $924.37
Upside: -43.20%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.56
Upside: +98.17%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $10.92
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $86.28
Upside: +7.79%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $24.23
Upside: +98.10%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.34
Upside: +1,840.30%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.28
Upside: +11,618.75%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $14.44
Upside: +440.17%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $120.24
Upside: -35.13%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $23.97
Upside: -24.91%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $131.16
Upside: +33.42%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $219.16
Upside: -69.89%